Synchron was founded in 2016 by Nicholas Opie and Thomas Oxley. Synchron has not officially endorsed or confirmed a plan to participate in an IPO.
Synchron is a bioelectric company that created neuromodulation technology for the medical treatment of brain and nervous system disorders. Per Forge data, Synchron has raised a total of $130 million in funding over 5 rounds, with their latest funding being raised on Dec 15, 2022, from a Series C round. Key investors include Khosla Ventures, Neurotechnology Investors, Sigma Partners, and ARCH Ventures.
These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
12/15/2022 | Series C-1 | $872,072.00 | $xx.xx | $400.53MM | Alumni Ventures, Arch Venture Partners, Bezos Expeditions, Forepoint Capital Partners, Gates Frontier, Greenoaks, Id8 Investments, Khosla Ventures, Metis, Moore Strategic Ventures, Neurotechnology Investors, Project X, Reliance Digital Health Limited, Shanda Group, University Of Melbourne | |
Price per Share
$xx.xx
Shares Outstanding
36,777
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alumni Ventures, Arch Venture Partners, Bezos Expeditions, Forepoint Capital Partners, Gates Frontier, Greenoaks, Id8 Investments, Khosla Ventures, Metis, Moore Strategic Ventures, Neurotechnology Investors, Project X, Reliance Digital Health Limited, Shanda Group, University Of Melbourne
|
||||||
12/15/2022 | Series C | $74.13MM | $xx.xx | $400.53MM | Alumni Ventures, Arch Venture Partners, Bezos Expeditions, Forepoint Capital Partners, Gates Frontier, Greenoaks, Id8 Investments, Khosla Ventures, Metis, Moore Strategic Ventures, Neurotechnology Investors, Project X, Reliance Digital Health Limited, Shanda Group, University Of Melbourne | |
Price per Share
$xx.xx
Shares Outstanding
2,657,210
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alumni Ventures, Arch Venture Partners, Bezos Expeditions, Forepoint Capital Partners, Gates Frontier, Greenoaks, Id8 Investments, Khosla Ventures, Metis, Moore Strategic Ventures, Neurotechnology Investors, Project X, Reliance Digital Health Limited, Shanda Group, University Of Melbourne
|
||||||
06/03/2021 | Series B-1 | $3.87MM | $xx.xx | $139.83MM | Arani Bose, Forepont Capital Partners, General Advance, Id8 Investments, Khosla Ventures, Metis, Neurotechnology Inestors, Re.Mind Capital, Shanda Group, Subversive Capital, Thomas Reardon, University Of Melbourne | |
Price per Share
$xx.xx
Shares Outstanding
360,658
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Arani Bose, Forepont Capital Partners, General Advance, Id8 Investments, Khosla Ventures, Metis, Neurotechnology Inestors, Re.Mind Capital, Shanda Group, Subversive Capital, Thomas Reardon, University Of Melbourne
|
||||||
06/03/2021 | Series B | $36MM | $xx.xx | $139.83MM | Arani Bose, Forepont Capital Partners, General Advance, Id8 Investments, Khosla Ventures, Metis, Neurotechnology Inestors, Re.Mind Capital, Shanda Group, Subversive Capital, Thomas Reardon, University Of Melbourne | |
Price per Share
$xx.xx
Shares Outstanding
2,849,155
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Arani Bose, Forepont Capital Partners, General Advance, Id8 Investments, Khosla Ventures, Metis, Neurotechnology Inestors, Re.Mind Capital, Shanda Group, Subversive Capital, Thomas Reardon, University Of Melbourne
|
||||||
04/04/2017 | Series A | $3.54MM | $xx.xx | $14.16MM | Darpa, Neurotechnology Investors | |
Price per Share
$xx.xx
Shares Outstanding
1,770,224
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Darpa, Neurotechnology Investors
|